Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's …
T Intragumtornchai, U Bunworasate… - Leukemia & …, 2006 - Taylor & Francis
With currently available combination chemotherapy regimens, the outcome of the patients
newly diagnosed with aggressive non-Hodgkin's lymphoma (NHL) identified as 'high'and …
newly diagnosed with aggressive non-Hodgkin's lymphoma (NHL) identified as 'high'and …
Rituximab (Rituxan) Combined with ESHAP Chemotherapy Is Highly Active in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma.
P Venugopal, SA Gretory, J Showel, J Shammo… - Blood, 2004 - Elsevier
Patients with relapsed/refractory aggressive lymphoma have limited options for achieving
long-term remission other than stem cell transplantation. ESHAP is active in aggressive NHL …
long-term remission other than stem cell transplantation. ESHAP is active in aggressive NHL …
Re-Treatment with Rituximab Plus Chemotherapy in Patients with Aggressive Lymphoma Treated Previously with CHOP or CHOP-Like Combinations Plus Rituximab.
A Palacios, M Navarrete, L Gallur, J Zuazu… - 2006 - ashpublications.org
Introduction. CHOP plus Rituximab has become the standard treatment for patients with
aggressive B-cell lymphoma-particularly DLBCL-, after having shown a better response rate …
aggressive B-cell lymphoma-particularly DLBCL-, after having shown a better response rate …
Six Courses of Intensified CHOP Plus G-CSF Compared to Eight Courses of Standard CHOP in Patients with Intermediate-Risk Aggressive Non-Hodgkin Lymphoma …
LF Verdonck, GW van Imhoff, JMM Raemakers… - 2005 - ashpublications.org
Abstract Between November 1994 and February 2004 a total of 513 untreated patients with
aggressive intermediate-risk NHL, aged 16–65 years, were recruited to the randomized …
aggressive intermediate-risk NHL, aged 16–65 years, were recruited to the randomized …
Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients
S Aydin, U Dührsen, H Nückel - Annals of hematology, 2007 - Springer
The anti-CD20 antibody rituximab improves the results of first-line therapy in aggressive non-
Hodgkin's lymphoma (NHL) of B cell lineage. The purpose of this retrospective study was to …
Hodgkin's lymphoma (NHL) of B cell lineage. The purpose of this retrospective study was to …
Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma
B Coiffier - Seminars in oncology, 2004 - Elsevier
In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
was considered the gold standard treatment for aggressive non-Hodgkin's lymphoma (NHL) …
was considered the gold standard treatment for aggressive non-Hodgkin's lymphoma (NHL) …
Recent developments in the treatment of aggressive non-Hodgkin lymphoma
AS Michallet, B Coiffier - Blood reviews, 2009 - Elsevier
Options for treating aggressive non-Hodgkin lymphoma (NHL) have expanded in recent
years. In phase 3 clinical trials, giving rituximab with cyclophosphamide, vincristine …
years. In phase 3 clinical trials, giving rituximab with cyclophosphamide, vincristine …
Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin's Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the …
P Sonneveld, W van Putten, H Holte, D Biesma… - 2005 - ashpublications.org
Abstract High-risk Non-Hodgkin lymphoma (NHL) in elderly patients (> 60 yrs) is associated
with a relatively low complete response (CR) rate and a poor overall survival (OS). Previous …
with a relatively low complete response (CR) rate and a poor overall survival (OS). Previous …
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10 …
F Frontzek, M Ziepert, M Nickelsen… - The Lancet …, 2021 - thelancet.com
Background R-MegaCHOEP was the first phase 3 study comparing high-dose
chemotherapy plus rituximab followed by autologous haematopoietic stem-cell …
chemotherapy plus rituximab followed by autologous haematopoietic stem-cell …
Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non …
RC Baldissera, M Nucci, AC Vigorito, A Maiolino… - Acta …, 2006 - karger.com
This prospective multicenter randomized trial compares conventional with early
intensification with high-dose sequential chemotherapy (HDS) and autologous stem cell …
intensification with high-dose sequential chemotherapy (HDS) and autologous stem cell …